Adaptive Biotechnologies has announced it has completed a series C financing round and completed a newly created series D round of financing with a $105 million investment from Viking Global Investors.

Adaptive Biotechnologies, based in Seattle, Wash., is an immunosequencing diagnostics company with a focus in oncology.

Viking Global Investors, based in Greenwich, Conn., is a global investment firm managing more than $20 billion in capital across long-short equity and long-only strategies.

The new funding for Adaptive Biotechnologies will be initially allocated to the expansion of the company’s immunoSEQ research platform through the launch of a research use only kit in the third quarter of 2014.